Kordonouri O, Danne T, Enders I, Weber B
Kliniken und Polikliniken für Kinderheilkunde und Kinderchirurgie, Charité-Virchow-Klinikum, Medizinische Fakultät der Humboldt Universität zu Berlin, Germany.
Eur J Pediatr. 1998 Mar;157(3):202-7. doi: 10.1007/s004310050796.
The objective of the present study was to investigate potential differences at presentation of type I diabetes and during its long-term clinical course in children and adolescents with prepubertal and pubertal manifestation. Clinical, immunological and biochemical characteristics at diabetes onset of 453 patients (320 prepubertal, 133 pubertal; median age at manifestation 7.1 years (0.7-13.9) and 13.1 years (9.2-17.6), respectively) were evaluated. Glycaemic control and exogenous insulin requirements were followed prospectively, with a median follow up of 9.4 years. At the onset of the disease no differences concerning the degree of metabolic decompensation, impairment of somatic health, and islet cell antibody status could be detected between the groups, except for a smaller body weight loss in pubertal patients (P=0.011). The duration of partial remission (insulin requirements <0.5 IU/kg body weight/day) was unrelated to age or pubertal status at onset. It was found to be longer in boys than in girls in the total cohort (median duration: 279 vs 215 days, P = 0.0071). Despite an absence of differences during the early course of the disease, glycaemic control was better, and daily insulin doses were significantly lower in patients with pubertal onset, after 6 years of diabetes.
Adolescents with a pubertal onset of type I diabetes have a more benign long-term course of the disease demonstrating better glycaemic control and lower insulin requirements, although the presentation of the disease at onset and its course during the first 6 years are not different from those of children with a prepubertal manifestation of diabetes.
本研究的目的是调查青春期前和青春期表现的儿童及青少年在1型糖尿病发病时及其长期临床过程中的潜在差异。评估了453例患者(320例青春期前患者,133例青春期患者;发病时的中位年龄分别为7.1岁(0.7 - 13.9岁)和13.1岁(9.2 - 17.6岁))糖尿病发病时的临床、免疫和生化特征。前瞻性地跟踪血糖控制和外源性胰岛素需求,中位随访时间为9.4年。在疾病发作时,除青春期患者体重减轻较小外(P = 0.011),两组之间在代谢失代偿程度、身体健康损害和胰岛细胞抗体状态方面未发现差异。部分缓解期(胰岛素需求<0.5 IU/kg体重/天)的持续时间与发病时的年龄或青春期状态无关。在整个队列中发现男孩的部分缓解期比女孩长(中位持续时间:279天对215天,P = 0.0071)。尽管在疾病早期过程中没有差异,但糖尿病发病6年后,青春期发病的患者血糖控制更好,每日胰岛素剂量显著更低。
青春期发病的1型糖尿病青少年患者的疾病长期病程更为良性,血糖控制更好,胰岛素需求更低,尽管疾病发作时的表现及其前6年的病程与青春期前表现的糖尿病儿童并无不同。